Back to peptide rules

Peptide rules in Oklahoma

Clinician reviewed regulatory status for compounds Scriptura covers publicly today. Additional compounds are reviewed inside the clinician tool.

Scriptura flags, alerts, and informs. The prescribing clinician makes every decision.
CompoundStatus in OklahomaVerifiedClinical review
CJC-1295 No-DACUnder active review2026-07-24Sabrina Runbeck, 2026-07-22
IpamorelinUnder active review2026-07-24Sabrina Runbeck, 2026-07-22
SemaglutideNo compound specific state restriction2026-07-22Sabrina Runbeck, 2026-07-22
TesamorelinNo compound specific state restriction2026-07-10Sabrina Runbeck, 2026-07-22
TirzepatideNo compound specific state restriction2026-07-22Sabrina Runbeck, 2026-07-22

The verified date is the date the reviewer confirmed the status against public sources. It is not a state board confirmation. The prescribing clinician owns the compliance decision.

Read the federal timeline for peptide compounding, July 2026.

Get Scriptura in your clinic

See how Scriptura pulls federal, state, and clinical sources into one reviewed view for prescribing clinicians. Book a live walkthrough, or get short updates when the rules move.

Reviewed by Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health.

Peptide rules in Oklahoma | Scriptura Health